

## [Bendamustine](#)

Statut de médicament essentiel

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

Codes ATC: [L01AA09](#)

Indication

Follicular lymphoma Code ICD11: [2B50.Z](#)

INN

Bendamustine

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

**Parenteral > General injections > unspecified:** 45 mg per 0.5 mL ; 180 mg per 2 mL

Historique des statuts LME

Ajouté pour la première fois en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Lire la suite [sur les brevets.](#)

Balises

Cancer

Wikipédia

[Bendamustine](#)

[DrugBank](#)

[Bendamustine](#)

Résumé des preuves et recommandation du comité d'experts



In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for follicular lymphoma. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for follicular lymphoma is attached.